International Stem Cell Corporation Planning European Subsidiary
International Stem Cell Corporation (OTCBB:ISCO) announced that it had entered into a Memorandum of Understanding with ARG Vermogensverwaltung AG ('ARG'), a German Investment Fund, to create a new European subsidiary ('ISCO Europe') to be funded with up to $10 million of capital derived from ARG... - July 28, 2010
International Stem Cell Corp. and India's Largest Eye Hospital to Develop Stem Cell-Based Treatment for Corneal Vision Impairment
International Stem Cell Corporation and Sankara Nethralaya Eye Hospital, a nonprofit medical facility, are collaborating to develop ISCO's 'CytoCor™' stem cell-derived corneal tissue. The goal is to use CytoCor, human tissue derived from pluripotent human stem cells, to treat corneal blindness and vision impairment. - July 11, 2010
International Stem Cell Corporation's Parthenogenetic Stem Cell Patent Approved by the United States Patent and Trademark Office
International Stem Cell Corporation announced that the United States Patent and Trademark Office has granted ISCO a patent relating to the company’s development of human non-embryonic parthenogenetic stem cells. Human parthenogenetic stem cells are a new type of pluripotent stem cell that allows immune matching to potentially solve critical immune rejection problems, that could create a universal cell benefiting most the of the world's population, and that avoids ethical issues. - June 10, 2010
International Stem Cell Corporation Enters Into Strategic Alliance to Automate Cornea Tissue Production
International Stem Cell Corporation (OTCBB:ISCO), www.intlstemcell.com, announced today that it had entered into a strategic alliance with The Automation Partnership (TAP), www.automationpartnership.com, to automate and scale up the production of stem cell-derived human corneal tissue. The alliance... - May 22, 2010
International Stem Cell and Absorption Systems Confirm Results Showing Stem Cell Derived Corneal Tissue as an Alternative to Animals for Drug Testing
International Stem Cell Corporation announced the results of a second set of experiments confirming that its lab-grown corneal tissue closely mimics the drug absorption and drug metabolism characteristics found in normal corneal tissue. Other tests show that the stem cell derived corneal tissue refracts light, signifying the potential therapeutic value in treating corneal injury and disease. - May 17, 2010
International Stem Cell Corporation Provides Strategic Update on Its Skin Care Program
International Stem Cell Corporation (ISCO.OB), announced that its wholly owned subsidiary, Lifeline Skin Care Inc., has achieved positive results in human safety tests of its cosmetic products and is moving forward with arrangements with Cosmetic Enterprises Ltd. for the manufacture of three... - April 11, 2010
International Stem Cell Corporation Begins Its Second Pre-Clinical Phase of Testing Retinal Pigment from Human Parthenogenetic Stem Cells
International Stem Cell Corporation, an international pioneer and leader in stem cell research, begins its second pre-clinical phase of testing retinal pigment epithelium (RPE) derived from human parthenogenetic stem cells for the treatment of retinal diseases. - March 24, 2010